Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (131-140 of 274) with videos related to

Pageof 28
Sort By:
Clinical Lung Cancer|October 27, 2015
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) DatabasePrimo N Lara, James Moon, Mary W Redman, et al.
American Journal of Clinical Oncology|June 3, 2009
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312Peter J Van Veldhuizen, Michael Hussey, Primo N Lara, et al.
Oncology (Williston Park, N.Y.)|July 31, 2003
Population-based maximum tolerated dose of irinotecan and carboplatinCarolyn A Wild, Stephen E Wang, David R Gandara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2007
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancerAngela M Davies, Cheryl Ho, Alex S Metzger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003Stephen K Williamson, John J Crowley, Primo N Lara, et al.
Cancer Investigation|March 20, 2003
Phase I trial of gemcitabine and paclitaxel in advanced solid tumorsNelson Lim, Primo N Lara, Derick H M Lau, et al.
International Journal of Nanomedicine|June 30, 2012
Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancerTzu-Yin Lin, Hongyong Zhang, Juntao Luo, et al.
Investigational New Drugs|October 23, 2010
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialTianhong Li, Scott D Christensen, Paul H Frankel, et al.
The Journal of Urology|April 18, 2009
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)Ralph W deVere White, Primo N Lara, Bryan Goldman, et al.
Kidney Cancer (Clifton, Va.)|March 12, 2019
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048Thomas J Semrad, Susan Groshen, Chunqiao Luo, et al.
Pageof 28

Showing results (131-140 of 274) with videos related to

Sort By:
Pageof 28
Clinical Lung Cancer|October 27, 2015
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) DatabasePrimo N Lara, James Moon, Mary W Redman, et al.
American Journal of Clinical Oncology|June 3, 2009
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312Peter J Van Veldhuizen, Michael Hussey, Primo N Lara, et al.
Oncology (Williston Park, N.Y.)|July 31, 2003
Population-based maximum tolerated dose of irinotecan and carboplatinCarolyn A Wild, Stephen E Wang, David R Gandara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2007
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancerAngela M Davies, Cheryl Ho, Alex S Metzger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003Stephen K Williamson, John J Crowley, Primo N Lara, et al.
Cancer Investigation|March 20, 2003
Phase I trial of gemcitabine and paclitaxel in advanced solid tumorsNelson Lim, Primo N Lara, Derick H M Lau, et al.
International Journal of Nanomedicine|June 30, 2012
Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancerTzu-Yin Lin, Hongyong Zhang, Juntao Luo, et al.
Investigational New Drugs|October 23, 2010
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialTianhong Li, Scott D Christensen, Paul H Frankel, et al.
The Journal of Urology|April 18, 2009
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)Ralph W deVere White, Primo N Lara, Bryan Goldman, et al.
Kidney Cancer (Clifton, Va.)|March 12, 2019
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048Thomas J Semrad, Susan Groshen, Chunqiao Luo, et al.
Pageof 28